NFKB1 and cancer: In the majority of cases, however, constitutive NF-κB activation in cancer occurs as a result of mutations in conventional oncogenes or tumor suppressors, such as RAS and PTEN, respectively, or inflammatory stimuli and other cues that originate from the tumor microenvironment (TME).